Applied Pharmaceutical Innovation Appoints Dr. Launa Aspeslet as Chief Translational Officer to Accelerate Life Sciences Commercialization in Canada
EDMONTON, Alberta, May 13, 2025 (GLOBE NEWSWIRE) -- Applied Pharmaceutical Innovation (API), one of Canada's leading life sciences commercialization organizations, is proud to announce the appointment of Dr. Launa Aspeslet as its first Chief Translational Officer.
Dr. Aspeslet has worked across the full spectrum of life sciences innovation, from small biotech startups to multinational pharmaceutical companies. Over the course of her career, she has spearheaded the advancement of multiple products from early-stage R&D through to FDA regulatory approval. In addition to leading hundreds of complex regulatory interactions across major global markets, bringing deep expertise in strategy, compliance, and execution, Dr. Aspeslet has also scaled a clinical research organization to global operations in over 20 countries, growing the team to more than 300 employees.
Having served as both an Advisor and Chair of API's Board in the past, Dr. Aspeslet has been an integral part of the organization's journey since its inception.
'With the momentum building in Alberta's life sciences sector—from homegrown success stories like Nanostics, Voyageur, and Pacylex, to major initiatives like the Canadian Critical Drug Initiative—there's never been a more important time to support early-stage companies ready to grow,' said Dr. Aspeslet. 'API has always played a critical role in bridging the gap between academia and industry. I'm excited to take on this new role and help lead API's transformation into a one-stop shop for early-stage innovators—from lead selection and proof-of-concept studies to clinical trials and product launch.'
A respected leader with nearly three decades of experience in the life sciences sector, Dr. Aspeslet brings deep expertise in regulatory strategy, clinical development, and scaling global biotech operations. In this newly created executive role, she will oversee API's regulatory affairs, pre-clinical and clinical development, quantitative solutions, and early product prototyping.
API Chief Executive Officer, Andrew MacIsaac emphasized the significance of this strategic appointment:
'Launa has been a driving force behind API from the very beginning, and her proven ability to take discoveries from the lab bench to market is unmatched,' said MacIsaac. 'She brings both vision and operational excellence, and her leadership in this new role will ensure we continue to meet the needs of scaling companies across Canada and beyond. This is a major step forward in our mission to make Canada—and particularly Alberta—a global hub for life sciences commercialization.'
As Alberta's life sciences ecosystem continues to gain global attention, API remains committed to empowering companies at all stages with the infrastructure, expertise, and strategic support they need to thrive.
About Applied Pharmaceutical Innovation (API):
API is one of Canada's largest not-for-profit commercialization organizations, dedicated to accelerating sector growth by helping innovators bring life-saving products to market.
API supports the full development and manufacturing lifecycle, from early-stage research to clinical trials and commercial production. Through a network of scientists, clinicians, and regulatory experts, API bridges the gap between academia and industry, assisting companies in commercializing pharmaceuticals, medical devices, natural health products and more. By fostering local talent and resources, API helps companies develop intellectual property within Canada and plays a leading role in securing Canada's supply of critical medicines while driving sustainable sector growth.
Media Enquiries:
Kris Panes
Associate, Brand Content
Applied Pharmaceutical Innovation
Email: [email protected]
Phone: 780-394-0832
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
TSplus Releases Server Monitoring Version 6 – A Major Step Forward in Remote Infrastructure Management
PARIS, May 30, 2025 (GLOBE NEWSWIRE) -- TSplus is proud to announce the official release of Server Monitoring Version 6, a major upgrade that reinforces its commitment to providing powerful and user-friendly tools for IT professionals managing remote infrastructures. Real-time Monitoring for Remote Work Infrastructures TSplus Server Monitoring is a real-time server and website monitoring solution designed to help IT teams monitor remote servers and online resources with ease. It enables administrators to collect and analyze both real-time and historical data about servers, websites, applications, and users. Key features include: Real-time Server Monitoring (performance, processes, bandwidth, user activity) Website Monitoring (availability and response time) Centralized Dashboard for all servers and websites Alerts Management (customizable alerts with email—and now SMS—notifications) Ready-to-use and customizable reports This powerful tool provides the visibility needed to ensure optimal performance, identify issues early, and support business continuity across remote environments. What's New in Version 6 to Monitor Remote Server With the release of Version 6, Server Monitoring gains valuable new capabilities to boost reliability and control. The most significant enhancement is agent-side data tracking: when a monitored server temporarily loses connection with the central console, the local agent continues tracking performance metrics and uploads the data once the link is restored—ensuring no monitoring gaps. Additional improvements in this version include: SMS alerting via Twilio, for instant, mobile notifications A new "Detailed Performance" report for deep analytics Visual alerts for stopped services and one-click restart from the dashboard Smarter database usage reporting and UI refinements 12 new language translations for better global accessibility including Czech, Spanish, Finnish, Italian, Turkish, and Chinese Version 6 is now also available through subscription licenses, in addition to the permanent licensing option, giving users ongoing access to all updates and new features. It is an ideal addition to the TSplus software suite—Remote Access, Advanced Security, and Remote Support—forming a complete solution to secure, access, monitor, and support any remote infrastructure. 'We designed Server Monitoring to give IT administrators the visibility and control they need to maintain performance and stability across their networks,' said Adrien Carbonne, TSplus CTO. 'Version 6 reflects the feedback and needs of our users, and we encourage customers to continue sharing their experiences to help us keep improving.' Learn more: Download and Try TSplus Server Monitoring for free at Press Contact: Caleb Zaharris Marketing Director at TSplus A photo accompanying this announcement is available at in to access your portfolio
Yahoo
26 minutes ago
- Yahoo
PESG Research Report: Revolutionary Surgical Infection Prevention: PolyPid's D-PLEX100 Approaches Critical Phase 3 Data Readout
New report from PESG Research brand covers PolyPid*, which is tackleing the $10 billion dollar a year surgeical site infections cost with its innovative PLEX technology New York, May 30, 2025 (GLOBE NEWSWIRE) -- PESG Research is releasing a report today examining PolyPid Ltd.*, an innovative late-stage biopharmaceutical company developing revolutionary localized drug delivery technologies for surgical infection prevention. The below report explores the company's breakthrough PLEX platform technology, its upcoming topline phase 3 data, and potential implications for transforming surgical care practices in the multi-billion dollar surgical site infection prevention market. This report contains sponsored content, please see refer to the disclaimers and disclosures included at the end of this report. Executive Summary The surgical site infection (SSI) prevention landscape stands at a potential inflection point as PolyPid Ltd. prepares to announce topline results from its pivotal SHIELD II Phase 3 trial by the end of Q2 2025. The company's D-PLEX100 represents a paradigm shift in infection prevention, utilizing novel polymer-lipid encapsulation matrix (PLEX) technology to deliver sustained antibiotic release directly at surgical sites for 30 days. With SSIs affecting up to 30% of colorectal surgeries and imposing substantial healthcare costs estimated at $10 billion annually in the US and EU, successful development of D-PLEX100 could address a critical unmet medical need. The FDA's assignment of Breakthrough Therapy, Fast Track, and Qualified Infectious Disease Product (QIDP) designations underscores the regulatory recognition of this approach's potential Critical Challenge of Surgical Site Infections Surgical site infections remain one of healthcare's most persistent challenges, representing 20% of all healthcare-associated infections in US hospitals. Despite advances in surgical techniques and prophylactic protocols, SSI rates in high-risk procedures like colorectal surgery can reach 30%, leading to extended hospital stays of 7-11 additional days and mortality risk increases of 2-11 fold. The economic burden is staggering, with direct costs averaging $11,000-26,000 per infection and total annual costs reaching approximately $10 billion in the US alone. Current prevention strategies rely primarily on systemic antibiotic prophylaxis administered intravenously 30-60 minutes before surgery. However, this approach faces fundamental limitations. Surgical incisions disrupt local blood flow, significantly limiting antibiotic penetration to the precise site where infections occur. Moreover, systemic administration exposes patients to higher drug concentrations throughout the body, potentially increasing toxicity risks and contributing to antimicrobial resistance development. PLEX Technology: A Novel Approach to Localized Drug Delivery PolyPid's proprietary PLEX technology represents a sophisticated advancement in controlled drug delivery systems. The platform creates thousands of alternating layers of biocompatible polymers and lipids that physically embed active pharmaceutical ingredients. As these outer layers gradually disintegrate upon exposure to body fluids, they enable precise, predetermined drug release rates spanning several days to months. For D-PLEX100, this technology pairs with doxycycline, a broad-spectrum antibiotic effective against both gram-positive and gram-negative bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and other antibiotic-resistant strains. The formulation achieves local antibiotic concentrations 10-115 times higher than systemic administration while using only a fraction of the total drug amount, potentially minimizing systemic exposure and associated side effects. Clinical Development Progress and Regulatory Recognition The clinical development program for D-PLEX100 has demonstrated encouraging signals across multiple surgical contexts. In Phase 2 abdominal surgery trials, D-PLEX100 plus standard of care achieved a statistically significant 59% reduction in the primary endpoint compared to standard of care alone (p=0.0086). Perhaps more notably, the treatment group experienced zero deaths compared to five in the control arm within 60 days post-surgery. The pivotal SHIELD I Phase 3 trial, while not meeting its primary endpoint in the full intent-to-treat population, revealed compelling efficacy in a pre-specified subgroup analysis. Among patients with large surgical incisions (>20 cm), D-PLEX100 demonstrated a statistically significant 54% reduction in the composite primary endpoint of SSIs, reinterventions, and mortality (p=0.0032). This finding directly informed the design of the ongoing SHIELD II trial, which focuses specifically on this higher-risk patient FDA's regulatory designations reflect recognition of D-PLEX100's potential significance. Breakthrough Therapy designation is reserved for drugs that demonstrate substantial improvement over existing treatments for serious conditions. Fast Track designation facilitates more frequent FDA communications and potentially accelerated review timelines. The QIDP designation provides additional market exclusivity incentives for addressing antimicrobial resistance challenges. SHIELD II: A Potentially Definitive Study The ongoing SHIELD II Phase 3 trial represents a carefully designed study incorporating lessons learned from SHIELD I. Following an independent Data Safety Monitoring Board's review of unblinded efficacy data from the first 430 enrolled patients, the board recommended concluding the study at 800 patients—the lowest sample size reassessment option available. This recommendation, while requiring additional enrollment beyond the initially planned 624 patients, may suggest positive efficacy trends in the analyzed interim data. The study's multinational design spans approximately 60 centers across the United States, Europe, and Israel, enhancing the generalizability of results across different healthcare settings and patient populations. The primary endpoint focuses on a composite of SSI events, reinterventions, and mortality within 30 days post-surgery, as adjudicated by an independent committee. Broader Industry ImplicationsSuccess of D-PLEX100 could catalyze broader adoption of localized drug delivery approaches in surgical settings. The technology's platform nature suggests potential applications beyond infection prevention, including localized chemotherapy delivery through the company's OncoPLEX program, currently in preclinical development for solid tumor treatment. The substantial market opportunity—with approximately 12 million eligible procedures annually in the US and 8 million in Europe—underscores the potential healthcare impact. PolyPid has already secured European commercialization rights through a partnership with Advanz Pharma, valued at up to $115 million plus royalties, while advancing discussions for US market partnerships. Conclusion As the pharmaceutical industry grapples with antimicrobial resistance and healthcare systems seek cost-effective solutions to persistent clinical challenges, D-PLEX100's approaching data readout represents a potentially significant milestone. The convergence of compelling preclinical and early clinical data, regulatory recognition, and substantial unmet medical need positions this development as one to monitor closely in the evolving landscape of surgical infection News Highlight from PolyPid: PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections >> Click here to Subscribe for more updates like this or go to * Legal Disclaimer & Disclosure: Nothing in this report constitutes medical, financial or any form professional or licensedadvice. This report is published by 'PESG Research', a digital promotional content brand who's operators are compensated to provide digestable and favorabel coverage of companies. This report contains and is a form of paid promotional content or advertising for PolyPid Ltd and was produced as part of the fee's they pay PESG's operators, Arx Advisory Ltd. This report has not been reviewed or approved by PolyPId prior to publication and it does not represent an official communication from PolyPid. The operators of PESG Research received or are expected to receive a monthly recurring fee of five thousand united states dollars via wire transfer from PolyPid as part of an ongoing agreement starting May 1, 2025 in return for distribution and promotional coverage services, and receive additional monthly compensation for non promotional unrelated data and advisory services on top of that. Please review the full disclaimers and compensation disclosures here for further details: Readers are advised to refer to the official materials of the company aforementioned. The report should not be treated as objective.
Yahoo
26 minutes ago
- Yahoo
IDT Corporation to Report Third Quarter 2025 Results
NEWARK, NJ, May 30, 2025 (GLOBE NEWSWIRE) -- IDT Corporation (NYSE: IDT), a global provider of fintech, cloud communications, and traditional communications solutions, has scheduled its report of financial and operational results for the third quarter fiscal year 2025 (the three months ended April 30, 2025) on Thursday, June 5, 2025. IDT's earnings release will be issued and posted on the IDT investor relations website ( at approximately 4:15 PM Eastern. IDT will host an earnings conference call beginning at 5:00 PM Eastern with management's discussion of results followed by Q&A with investors. To listen to the call and participate in the Q&A, dial 1-888-506-0062 (toll-free from the US) or 1-973-528-0011 (international) and provide the following access code: 491722. A replay of the conference call will be available approximately three hours after the call concludes through June 19, 2025. To access the call replay, dial 1-877-481-4010 (toll-free from the US) or 1-919-882-2331 (international) and provide this replay passcode: 52353. The replay will also be accessible via streaming audio at the IDT investor relations website. ABOUT IDT CORPORATION IDT Corporation (NYSE: IDT) is a global provider of fintech and communications solutions through a portfolio of synergistic businesses: National Retail Solutions (NRS), through its point-of-sale (POS) platform, enables independent retailers to operate more effectively while providing advertisers and marketers with unprecedented reach into underserved consumer markets; BOSS Money facilitates innovative international remittances and fintech payments solutions; net2phone provides enterprises and organizations with intelligently integrated cloud communications and contact center services across channels and devices; IDT Digital Payments and the BOSS Revolution calling service make sharing prepaid products and services and speaking with friends and family around the world convenient and reliable; and, IDT Global and IDT Express enable communications services to provision and manage international voice and SMS messaging. Contact: Bill Ulrey IDT Investor Relations Phone: (973) 438-3838 E-mail: invest@ ###
